Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
26/06/2020 13:55
June 26 (Reuters) - Helix Biopharma Corp HBP.TO :
* PRESS RELEASE - HELIX BIOPHARMA CORP. TO DIVEST REMAINING
OWNERSHIP OF POLISH SUBSIDIARY
* HELIX BIOPHARMA - HAS ENTERED INTO A NON-BINDING TERM
SHEET TO
DIVEST REMAINING SHARES IT HOLDS IN ITS POLISH SUBSIDIARY HELIX
IMMUNO-ONCOLOGY S.A.
Source text for Eikon: ID:nGNX9GWTSD
Further company coverage: HBP.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020